Introduction – Addressing Core Industry Pain Points
The global biomedical research industry faces a persistent challenge: sourcing reliable, genetically defined, and ethically produced animal models for drug development, disease research, and genetic studies. Researchers, pharmaceutical companies, and academic institutions require experimental animals with known genetic backgrounds, consistent phenotypes, and documented health status to ensure reproducible results. Laboratory mice (white mice) are a type of house mouse (Mus musculus, derived from Eastern European and Western European subspecies) domesticated specifically for animal experiments. They offer relatively low cost, rapid growth, easy husbandry, and strong fecundity (litter size 6-12, gestation 19-21 days), making them the most widely used experimental animals in biomedical research. Key applications include oncology (xenograft models), immunology (humanized mice), neuroscience (behavioral models), metabolic disease (obesity/diabetes models), and infectious disease research. Genetically modified strains (transgenic, knockout, knock-in, humanized) enable mechanistic studies of human disease pathways and preclinical drug efficacy testing. Global Leading Market Research Publisher QYResearch announces the release of its latest report “White Mouse – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global White Mouse market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) 】
https://www.qyresearch.com/reports/5986031/white-mouse
Market Sizing & Growth Trajectory
The global market for White Mouse was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. According to QYResearch’s interim tracking (January–June 2026), the market is driven by: (1) increasing global R&D spending in pharmaceuticals and biotechnology (estimated $200B+ annually), (2) growth in personalized medicine and immuno-oncology research requiring humanized mouse models, (3) expansion of CRISPR/Cas9 gene editing enabling faster model generation. The transgenic mice segment dominates (45-50% market share), followed by humanized mice (25-30%) and others (inbred, outbred, immunodeficient – 20-25%). Scientific research centers (academic institutions, research institutes) account for 40-45% of demand, universities 25-30%, companies (pharma, biotech, CROs) 20-25%, and others 5-10%.
独家观察 – Mouse Model Categories and Research Applications
| Model Type | Genetic Modification | Key Characteristics | Primary Research Applications | Generation Time | Cost per Model (relative) |
|---|---|---|---|---|---|
| Humanized Mice | Human genes, cells, or immune system engrafted | Human immune function, human target expression | Immuno-oncology (PDX, CDX), infectious disease (HIV, HBV), drug metabolism | 6-12 months | High ($$$$) |
| Transgenic Mice | Foreign DNA inserted into genome | Overexpression or expression of human/novel genes | Gene function studies, disease models (Alzheimer’s, cancer), reporter lines | 6-9 months | High ($$$) |
| Knockout/Knock-in | Targeted gene disruption or replacement | Loss of function, point mutations, conditional alleles | Gene function, disease modeling, drug target validation | 9-18 months | High ($$$$) |
| Inbred Strains (C57BL/6, BALB/c) | No transgene (genetically uniform) | Genetic consistency, reproducible phenotypes | Baseline studies, immunology, toxicology, aging | N/A (commercial) | Low ($) |
| Immunodeficient (NSG, NOG, nude) | Multiple immune gene mutations | Absent T, B, NK cells for xenograft engraftment | Xenograft tumor models (PDX, CDX), stem cell research | N/A (commercial) | High ($$-$$$) |
From a biological production perspective (colony breeding, barrier facilities), laboratory mouse production differs from other laboratory animals (rats, rabbits, guinea pigs, non-human primates) through: (1) shorter generation time (2-3 months to sexual maturity), (2) higher litter size (6-12 pups), (3) lower housing density (3-5 mice per cage vs. 1 rabbit per cage), (4) lower cost per animal ($10-500 vs. $50-5,000+ for larger species), (5) extensive genetic characterization available.
Six-Month Trends (H1 2026)
Three trends reshape the market: (1) Humanized immune system mice – NSG and related strains engrafted with human CD34+ hematopoietic stem cells enabling study of human immune responses to cancer immunotherapies (PD-1, CAR-T, bispecific antibodies); (2) CRISPR efficiency improvements – Base editing and prime editing enabling precise single-nucleotide modifications without double-strand breaks, reducing off-target concerns; (3) Asian market expansion – Chinese model organism centers (GemPharmatech, Shanghai Model Organisms Center, Cyagen) expanding capacity and global distribution, offering cost-competitive alternatives to US/European suppliers.
User Case Example – Immuno-Oncology Drug Development, United States
A mid-sized biotech company developing a novel PD-1/CTLA-4 bispecific antibody used humanized immune system mice (NSG-SGM3 engrafted with human CD34+ cells, Jackson Laboratory supply) for preclinical efficacy testing. Study design: 80 mice (40 treated, 40 control), human tumor xenograft (patient-derived melanoma), 6-week treatment course. Results (completed Q1 2026): tumor growth inhibition 78% (treated vs. control); survival benefit observed (median 45 days vs. 28 days); immune cell infiltration (CD8+ T cells) confirmed in tumor biopsies. Data supported IND filing (expected Q3 2026). Model cost $450 per mouse ($36,000 total study cost) – considered cost-effective vs. non-human primate studies ($50,000-150,000 per animal).
Technical Challenge – Genetic Drift and Colony Management
A key technical challenge for laboratory mouse production and research is maintaining genetic stability and health status across generations:
| Challenge | Impact | Mitigation Strategy |
|---|---|---|
| Genetic drift | Spontaneous mutations accumulating over generations, altering phenotype | Periodic genetic monitoring (SNP panels, whole genome sequencing), cryopreservation of early generation embryos |
| Microbiological contamination (viruses, bacteria, parasites) | Immunomodulation, altered research outcomes, colony loss | Barrier facilities (HEPA filtration, positive pressure), sentinel monitoring (FELASA, AAALAC standards), quarantine |
| Reproductive performance decline | Reduced litter size, delayed breeding | Optimized nutrition, light cycle control (12:12), veterinary oversight |
| Phenotype variability | Inconsistent experimental results | Standardized husbandry (diet, bedding, enrichment), littermate controls, randomization |
Commercial suppliers (Jackson Laboratory, Taconic, GemPharmatech, Charles River – not listed but major) maintain genetic quality through: (1) rigorous foundation colonies, (2) defined genetic monitoring protocols (quarterly SNP panels), (3) cryopreserved embryo archives for restocking.
独家观察 – Customer Segment Requirements
| Parameter | Scientific Research Center | University | Company (Pharma/Biotech/CRO) |
|---|---|---|---|
| Typical order size | 10-500 mice | 5-200 mice | 100-5,000+ mice |
| Model preference | Standard inbred, knockout | Transgenic, conditional | Humanized, immunodeficient, PDX |
| Price sensitivity | High (grant-funded) | High (grant-funded) | Low-moderate (industry-funded) |
| Lead time tolerance | 2-8 weeks | 2-8 weeks | 1-4 weeks (urgent studies) |
| Technical support | Moderate | Moderate-High | High (study design, data interpretation) |
| Reorder frequency | Weekly-monthly | Monthly | Weekly (high-throughput screening) |
| Key suppliers (listed) | GemPharmatech, Shanghai Model Organisms, Cyagen, PolyGene | Taconic, Czech Breeding Company, GemPharmatech | Jackson Laboratory, Taconic, GemPharmatech, Ozgene |
Downstream Demand & Competitive Landscape
Applications span: Scientific Research Center (academic research institutes, government labs, non-profit research organizations – largest segment, 40-45%), University (academic teaching and research labs – 25-30%), Company (pharmaceutical, biotechnology, contract research organizations – 20-25%, fastest-growing for humanized/transgenic models), Others (regulatory testing, contract breeding, zoos). Key players: GemPharmatech Co., Ltd. (China, large-scale CRISPR model production), Shanghai Model Organisms Center, Inc. (China), Cyagen (China/US, custom model generation), Ozgene (Australia, custom transgenic), Taconic (US/Europe, commercial models, barrier colonies), Czech Breeding Company (Europe, commercial breeding), GemPharmatech (listed twice), THE JACKSON LABORATORY (US, world leader, repository of >12,000 mouse strains, gold standard for genetic quality), PolyGene (Switzerland, custom models).
Segmentation Summary
The White Mouse market is segmented as below:
Segment by Type – Humanized Mice (immune-oncology, infectious disease), Transgenic Mice (largest, 45-50%, gene function, disease models), Others (inbred, outbred, knockout, conditional, immunodeficient)
Segment by Application – Scientific Research Center (largest, 40-45%), University (25-30%), Company (20-25%, fastest-growing), Others (5-10%)
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
